Jordi Badia

With a successful business career in life sciences spanning over twenty-five years, Jordi is a seasoned international executive with experience in running global biopharmaceutical businesses.

Before founding Orphan Now, Jordi spent several years at Alexion Pharmaceuticals as its European commercial head and general manager. He played a critical role in the setup and expansion of Alexion, as well as in the launch of Soliris® (eculizumab) in the EMEA Region. Jordi joined Alexion after working as the head of global marketing at Almirall, where he managed the company’s product portfolio internationally and led the establishment of its commercial operations in Europe and Latin America. Additionally, Jordi worked at Abbott Laboratories’ world headquarters in Chicago, where he drove the international launch of Synagis® (palivizumab) in his position as a global brand leader. Before working for Abbott, he spent eight years at Novartis, initially as a corporate financial controller at its headquarters in Basel, Switzerland, and later as Novartis’ China business development director at its Beijing office.

Jordi received an MBA from the Kelley School of Business at Indiana University at Bloomington. He was recognized for his international academic excellence with a Kelley’s Global Achievement Award. Jordi also earned a license of law from the Universidad de Barcelona School of Law.

Jordi has been a member of the faculty at the Kelley School of Business at Indiana University for several years. His research and teaching focused on business economics and public policy issues regarding rare diseases and the biopharmaceutical industry. He also served on the advisory board of the Kelley School’s Center for the Business of Life Sciences. Jordi is a member of the Luxembourg Business Angel Network. He has been a member of the Barcelona Bar Association since 1990.